Literature DB >> 8067646

Tissue cytokine patterns in patients with polymyalgia rheumatica and giant cell arteritis.

C M Weyand1, K C Hicok, G G Hunder, J J Goronzy.   

Abstract

OBJECTIVE: To analyze temporal artery specimens from patients with giant cell arteritis and polymyalgia rheumatica for the presence of inflammatory cytokines and to ascertain whether a specific cytokine pattern exists for the two conditions.
DESIGN: Case series of patients having temporal artery biopsy procedures.
SETTING: The outpatient clinic and the research laboratories of the Division of Rheumatology, Mayo Clinic. PATIENTS: 34 patients having temporal artery biopsy procedures: 15 patients had giant cell arteritis, 9 had polymyalgia rheumatica without evidence of vasculitis, and 10 had neither polymyalgia rheumatica nor vasculitis. MEASUREMENT: Temporal artery specimens were analyzed for in vivo presence of cytokine messenger RNA (mRNA) by polymerase chain reaction with cytokine-specific primer sets.
RESULTS: Vasculitic lesions in giant cell arteritis samples were characterized by in situ production of interleukin-1 beta, interleukin-6, and transforming growth factor-beta 1 mRNA (indicative of macrophage activation) and by interferon-gamma and interleukin-2 mRNA (indicative of selective T-cell activation). However, macrophage- and T-cell-derived cytokines were also detected in temporal artery biopsy specimens from patients with polymyalgia rheumatica. Tissue-infiltrating T cells in giant cell arteritis and polymyalgia rheumatica samples each had distinctive lymphokine profiles. Although interferon-gamma was found in 67% of giant cell arteritis samples, polymyalgia rheumatica samples had only interleukin-2.
CONCLUSIONS: Patients with polymyalgia rheumatica have vascular involvement. Patients with polymyalgia rheumatica and giant cell arteritis share in situ production of mRNA specific for macrophage-derived cytokines. T cells recruited to vasculitic lesions in patients with giant cell arteritis predominantly produce interleukin-2 and interferon-gamma. Patients with polymyalgia rheumatica do not have interferon-gamma production, suggesting that interferon-gamma may be involved in the progression to overt arteritis.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8067646     DOI: 10.7326/0003-4819-121-7-199410010-00003

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  72 in total

1.  Formation of new vasa vasorum in vasculitis. Production of angiogenic cytokines by multinucleated giant cells.

Authors:  M Kaiser; B Younge; J Björnsson; J J Goronzy; C M Weyand
Journal:  Am J Pathol       Date:  1999-09       Impact factor: 4.307

Review 2.  Rare diseases.3: Wegener's granulomatosis.

Authors:  C A Langford; G S Hoffman
Journal:  Thorax       Date:  1999-07       Impact factor: 9.139

3.  Giant Cell Arteritis.

Authors: 
Journal:  Curr Treat Options Cardiovasc Med       Date:  2000-06

Review 4.  Giant cell arteritis.

Authors:  J M Calvo-Romero
Journal:  Postgrad Med J       Date:  2003-09       Impact factor: 2.401

5.  Parameters related to a positive test result for FDG PET(/CT) for large vessel vasculitis: a multicenter retrospective study.

Authors:  G A Hooisma; H Balink; P M Houtman; R H J A Slart; K D F Lensen
Journal:  Clin Rheumatol       Date:  2012-02-10       Impact factor: 2.980

Review 6.  [Polymyalgia rheumatica: myalgic syndrome or occult vasculitis?].

Authors:  B Hellmich; W L Gross
Journal:  Internist (Berl)       Date:  2005-11       Impact factor: 0.743

7.  Treatment of refractory temporal arteritis with adalimumab.

Authors:  M Mubashir Ahmed; Eisha Mubashir; Samina Hayat; Marjorie Fowler; Seth Mark Berney
Journal:  Clin Rheumatol       Date:  2006-08-30       Impact factor: 2.980

Review 8.  Lower extremity vasculitis in polymyalgia rheumatica and giant cell arteritis.

Authors:  Tanaz A Kermani; Kenneth J Warrington
Journal:  Curr Opin Rheumatol       Date:  2011-01       Impact factor: 5.006

Review 9.  Giant cell arteritis and polymyalgia rheumatica: pathophysiology and management.

Authors:  Miguel A Gonzalez-Gay; Carlos Garcia-Porrua; Jose A Miranda-Filloy; Javier Martin
Journal:  Drugs Aging       Date:  2006       Impact factor: 3.923

Review 10.  Pro-inflammatory and anti-inflammatory T cells in giant cell arteritis.

Authors:  Ryu Watanabe; Ebru Hosgur; Hui Zhang; Zhenke Wen; Gerald Berry; Jörg J Goronzy; Cornelia M Weyand
Journal:  Joint Bone Spine       Date:  2016-09-20       Impact factor: 4.929

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.